BRCi001-A

Registration Summary:

A P E C

The release of the cell line is on hold until 2019-10-01T00:00:00

(only basic data is shown)

General

iPSC Line
hPSCreg name	BRCi001-A
Cite as:	BRCi001-A (RRID:CVCL_UN30)
iPSC line type	Human induced pluripotent stem cell (hiPSC)
Similar iPSC lines	No similar lines found.
Last update	22nd May 2019
User feedback	Written by on No feedback available yet. Login to share your feedback, experiences or results with the research community.
Provider
Generator	RIKEN BioResource Research Center (BRC)
Owner	Center for iPS Cell Research and Application (CIRA)
Distributors	RIKEN BioResource Research Center (BRC)
External iPSC Databases
BioSamples	SAMEA5141620
Cellosaurus	CVCL_UN30
Wikidata	Q94219283
General iPSC Information
Publications	Suga M et al. Generation of a human induced pluripotent stem cell line, BRCi001-A, derived from a patient with mucopolysaccharidosis type I. Stem cell research. 2019 Apr;36:101406. Santos HS et al. Genome editing in mucopolysaccharidoses and mucolipidoses. Progress in molecular biology and translational science. 2021;182:327-351. Rim YA et al. Characterization of Early-Onset Finger Osteoarthritis-Like Condition Using Patient-Derived Induced Pluripotent Stem Cells. Cells. 2021 Feb 4;10(2). Carvalho Sofia et al. Neurological Disease Modeling Using Pluripotent and Multipotent Stem Cells: A Key Step towards Understanding and Treating Mucopolysaccharidoses. Biomedicines. 2023-04-21. Placci Marina et al. Polymer-based drug delivery systems under investigation for enzyme replacement and other therapies of lysosomal storage disorders. Advanced Drug Delivery Reviews. 2023-06-00. Mizuno-Iijima S et al. Mammalian genome research resources available from the National BioResource Project in Japan. Mammalian genome : official journal of the International Mammalian Genome Society. 2024 Dec;35(4):497-523.
* Is the cell line readily obtainable for third parties?	Yes Research use: allowed Clinical use: not allowed Commercial use: not allowed

iPSC Derivation

General